📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
News
Sygnature Discovery nommée Entreprise de l’année lors des prix annuels de Bionow
Sygnature Discovery est ravie d’annoncer qu’elle a été nommée Entreprise de l’année lors des Bionow…
News
Powerful Webinar Series Unites Sygnature and Altasciences
Sygnature has joined forces with Altasciences, a CRO/CDMO in the U.S. and Canada specializing…
Blog
NASH – a disease on the rise with no available drug treatment
Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease…
Technical Notes
Blood Plasma Partitioning
Learn about the impact of drug binding to red blood cells (RBC) and plasma proteins on pharmacokinetics. Discover how RBC binding can affect drug concentration, pharmacological action, and potential toxicity. Understand the importance of early assessment during drug discovery.
Technical Notes
Metabolite Profiling
Drug Metabolism Insights: Explore Metabolite Profiling with Sygnature Discovery. Discover how liver metabolism influences drug clearance, and how Sygnature's specialized assays, utilizing hepatocytes, microsomes, and more, can guide your drug discovery project. Predict in vivo hepatic clearance, identify key metabolic pathways, and optimise administration strategies for enhanced therapeutic outcomes.
Technical Notes
Reaction Phenotyping
Enhance drug efficacy with Reaction Phenotyping using efficient Bactosomes. Predict interactions & optimise metabolism variability.
Technical Notes
Aqueous solubility – turbidimetric / kinetic – thermodynamic
Discover the importance of aqueous solubility in drug discovery and development. Overcome low solubility obstacles with our kinetic and thermodynamic solubility assays. Improve drug absorption and formulation. Explore our DMPK/ADME capabilities now!
Technical Notes
CYP Induction (mRNA) / HepaRG
Uncover CYP induction's impact on drug interactions & metabolism. Stay FDA-compliant with CYP1A2, CYP2B6, & CYP3A4 investigations.
Technical Notes
Cytotoxicity testing
Discover precise cytotoxicity testing with Sygnature's Cell Viability assay. Efficient, innovative, and informed drug safety assessment.
Technical Notes
In vivo PK / Pharmacokinetic studies
Explore In Vivo Pharmacokinetic (PK) Studies: Learn about drug absorption, distribution, metabolism, and elimination (ADME). Discover the key parameters - AUC, Cmax, t½, Vss, and clearance - in early-stage drug development. Uncover insights into oral bioavailability and first-pass hepatic elimination. Enhance your understanding of PK through detailed ADME analysis and renal/biliary clearance studies.
Technical Notes
Dietary-Induced obese (DIO) mice and rat model
Explore our ready-to-use Dietary-Induced Obese (DIO) mouse and rat models, perfect for assessing weight loss interventions and testing novel treatments. Our DIO mouse model boasts stable weight, significant adiposity, insulin resistance, lipid deposition, and elevated plasma lipids. Experience proven predictive validity in a 4-week study, showcasing the effectiveness of semaglutide. Additionally, our DIO rat model, replicating a calorie-dense Western diet, offers excellent predictive validity with on-demand production in just 16 weeks.
Technical Notes
Glucocorticoid-induced model of insulin resistance
Explore our rapid model of glucocorticoid-induced insulin resistance, ideal for testing antidiabetic potential of new drugs. Witness the inhibitory effects of mifepristone and CORT125134 on insulin resistance and hyperglycaemia in rats.
Technical Notes
Genetic models of insulin resistance and type 2 diabetes
Explore our genetic models of insulin resistance and type 2 diabetes. Our expertise lies in working with animal models predisposed to these conditions, such as ob/ob mice, db/db mice, and Zucker fatty rats. Discover how liraglutide, a clinically approved treatment, mitigates the progression of diabetes in the db/db mouse model. Our standard readouts include glucose tolerance tests and pancreatic insulin quantification. Uncover insights into therapeutic interventions and better understand diabetes-related phenotypes.
Technical Notes
Streptozotocin (STZ) high fat diet (HFD) model of diabetes
We have developed a robust and reproducible model of diabetes that combines exposure to a…
Technical Notes
Acute feeding studies
Hypophagic potential: Acute Feeding Studies with novel drugs in mice and rats. Rapid assessment, various routes, up to 7-day evaluation. Discover ED50 values & pharmacokinetics. Advance drug development
Technical Notes
Assessment of Energy Expenditure
The mechanisms underlying the reduction in body weight produced by novel anti-obesity drugs should always…
Technical Notes
Body composition analysis to determine specificity of weight loss
Explore body composition analysis for weight loss assessment in mice, differentiating fat loss from harmful water and protein reduction. Methods include DEXA and gold-standard techniques for valuable insights into interventions and drug effects.
Technical Notes
Behavioural aspects of feeding to explore specificity of effects on food intake
Discovering specific effects on food intake: Satiation profiling and pica assessment help identify potential anti-obesity agents.
Technical Notes
Sitagliptin Improves Glucose Tolerance in Insulin-Resistant Rodents
Measure glucose tolerance routes in rodents, assess insulin sensitivity, and test antidiabetic potential with Sitagliptin in insulin-resistant models.
Technical Notes
Assessment of gastric emptying rate to explore mechanisms of satiety and reduced food intake
Explore the mechanisms of satiety and reduced food intake through gastric emptying rate assessment. Our direct and indirect models offer insights into drug effects. Validate with clinical opioid agonist loperamide.
Technical Notes
Adriamycin-induced model of focal segmental glomerulosclerosis (FSGS) and fibrosis
Explore the Adriamycin-induced Model of Focal Segmental Glomerulosclerosis (FSGS) and Fibrosis. Discover how this rodent model mimics human proteinuric kidney disease, offering quick induction of renal injury and a customizable study design for prevention or reversal of the phenotype. Witness the demonstrated effectiveness of Enalapril in preventing and partially reversing the adriamycin-induced phenotype. Unravel new insights into FSGS research today.
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch